<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Alethia Biotherapeutics</title>
	<atom:link href="http://alethiabio.com/feed/" rel="self" type="application/rss+xml" />
	<link>http://alethiabio.com</link>
	<description></description>
	<lastBuildDate>Thu, 16 May 2013 02:36:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	
		<item>
		<title>May 16, 2013</title>
		<link>http://alethiabio.com/may-16-2013-3/</link>
		<comments>http://alethiabio.com/may-16-2013-3/#comments</comments>
		<pubDate>Thu, 16 May 2013 02:36:06 +0000</pubDate>
		<dc:creator>Mario</dc:creator>
				<category><![CDATA[2013]]></category>
		<category><![CDATA[Press Release]]></category>

		<guid isPermaLink="false">http://alethiabio.com/?p=1035</guid>
		<description><![CDATA[Alethia Biotherapeutics Announces the Issuance of a United States Patent for Monoclonal Antibodies Targeting Secreted Clusterin for Inhibition of EMT Alethia 130516 EN]]></description>
			<content:encoded><![CDATA[<p>Alethia Biotherapeutics Announces the Issuance of a United States Patent for Monoclonal Antibodies Targeting Secreted Clusterin for Inhibition of EMT</p>
<p><a href="http://alethiabio.com/wp-content/uploads/2013/05/Alethia-130516-EN.pdf">Alethia 130516 EN</a></p>
]]></content:encoded>
			<wfw:commentRss>http://alethiabio.com/may-16-2013-3/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Research Assistant for Research Group</title>
		<link>http://alethiabio.com/research-assistant-for-research-group-2/</link>
		<comments>http://alethiabio.com/research-assistant-for-research-group-2/#comments</comments>
		<pubDate>Tue, 19 Mar 2013 14:15:21 +0000</pubDate>
		<dc:creator>Mario</dc:creator>
				<category><![CDATA[Careers]]></category>

		<guid isPermaLink="false">http://alethiabio.com/?p=990</guid>
		<description><![CDATA[Reports to: Senior Scientist Location: Montréal, Québec Job Summary: Cellular and molecular biologist. A research assistant is responsible for executing research and experimentation on scientific projects prioritized by the organization. He or she assists in the experimental designs, conducts experiments and analyzes data. Position [...]]]></description>
			<content:encoded><![CDATA[<p><strong>Reports to: </strong>Senior Scientist</p>
<p><strong>Location:</strong> Montréal, Québec</p>
<p><strong>Job Summary:</strong> <strong>Cellular and molecular biologist.</strong> A research assistant is responsible for executing research and experimentation on scientific projects prioritized by the organization. He or she assists in the experimental designs, conducts experiments and analyzes data.</p>
<p><strong>Position status: </strong>This position is full-time (i.e. 5 days per week) pour a month period, or more</p>
<p><strong>General Duties and Responsibilities:</strong></p>
<ul>
<li>Prepares protocols</li>
<li>Records scientific data by producing electronic experimental reports in an organized and timely manner</li>
<li>Contributes to the process of a project within his or her scientific discipline, as well as assisting in the development of new methods and technologies for project advancement.</li>
<li>Participates in internal scientific laboratory meetings.</li>
<li>Contributes to the general organization of the laboratory.</li>
</ul>
<p><strong>Education / Qualifications:</strong></p>
<ul>
<li>At the entry level, the job requires a bachelor or a Master’s degree in science or equivalent work experience.</li>
<li>2-3 year work experience is required.</li>
</ul>
<p><strong>General Skills and Abilities:</strong></p>
<ul>
<li>Experience in molecular biology techniques including PCR, DNA cloning and mutagenesis, western blotting and ELISA. The candidate should be able to demonstrate expertise in both conducting and designing such experiments.</li>
<li>Experience maintaining and conducting experiments with cell lines using routine tissue culture techniques.</li>
<li>Basic scientific writing skills.</li>
<li>Computer skills and competencies in word processing, spreadsheets, presentation software, and on-line scientific searching.</li>
<li>Knowledge of French and English.</li>
</ul>
<p><strong>Key Responsibilities and Tasks:</strong></p>
<ul>
<li>Preparation of plasmid expression vectors for expression of potential drug targets (cloning, mutagenesis, western blotting, etc.).</li>
<li>Analysis of the function of potential drug targets in cell lines (proliferation and differentiation assays, gene and protein expression analysis by western blotting and RT-PCR, etc.).</li>
<li>Assist with laboratory organization.</li>
</ul>
<p><strong>Please note, only selected candidates will be contacted</strong></p>
]]></content:encoded>
			<wfw:commentRss>http://alethiabio.com/research-assistant-for-research-group-2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>March 11-13, 2013</title>
		<link>http://alethiabio.com/march-11-13-2013/</link>
		<comments>http://alethiabio.com/march-11-13-2013/#comments</comments>
		<pubDate>Thu, 28 Feb 2013 20:05:33 +0000</pubDate>
		<dc:creator>Mario</dc:creator>
				<category><![CDATA[2013]]></category>
		<category><![CDATA[Non classé]]></category>

		<guid isPermaLink="false">http://alethiabio.com/?p=948</guid>
		<description><![CDATA[Alethia Biotherapeutics to be part of the BIO Europe Spring 2013 Annual International Partnering Conference in Barcelona, Spain. Yves Cornellier and Mario Filion will be in attendance.]]></description>
			<content:encoded><![CDATA[<p>Alethia Biotherapeutics to be part of the BIO Europe Spring 2013 Annual International Partnering Conference in Barcelona, Spain.</p>
<p>Yves Cornellier and Mario Filion will be in attendance.</p>
]]></content:encoded>
			<wfw:commentRss>http://alethiabio.com/march-11-13-2013/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>February 28, 2013</title>
		<link>http://alethiabio.com/february-28-2013/</link>
		<comments>http://alethiabio.com/february-28-2013/#comments</comments>
		<pubDate>Thu, 28 Feb 2013 16:29:13 +0000</pubDate>
		<dc:creator>Mario</dc:creator>
				<category><![CDATA[2013]]></category>

		<guid isPermaLink="false">http://alethiabio.com/?p=915</guid>
		<description><![CDATA[Alethia Biotherapeutics Announces Notice of Allowance of a United States Patent for Monoclonal Antibodies Targeting Secreted Clusterin for Inhibition of EMT Alethia 130228 EN]]></description>
			<content:encoded><![CDATA[<p>Alethia Biotherapeutics Announces Notice of Allowance of a United States Patent for Monoclonal Antibodies Targeting Secreted Clusterin for Inhibition of EMT</p>
<p><a href="http://alethiabio.com/wp-content/uploads/2013/02/Alethia-130228-EN.pdf">Alethia 130228 EN</a></p>
]]></content:encoded>
			<wfw:commentRss>http://alethiabio.com/february-28-2013/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>February 19, 2013</title>
		<link>http://alethiabio.com/alethia-biotherapeutics-announces-issuance-of-a-japanese-patent-for-monoclonal-antibodies-targeting-siglec-15/</link>
		<comments>http://alethiabio.com/alethia-biotherapeutics-announces-issuance-of-a-japanese-patent-for-monoclonal-antibodies-targeting-siglec-15/#comments</comments>
		<pubDate>Tue, 19 Feb 2013 12:52:22 +0000</pubDate>
		<dc:creator>Mario</dc:creator>
				<category><![CDATA[2013]]></category>
		<category><![CDATA[Press Release]]></category>

		<guid isPermaLink="false">http://alethiabio.com/?p=890</guid>
		<description><![CDATA[Alethia Biotherapeutics Announces Issuance of a Japanese Patent for Monoclonal Antibodies Targeting Siglec-15 Alethia 130219 EN]]></description>
			<content:encoded><![CDATA[<p>Alethia Biotherapeutics Announces Issuance of a Japanese Patent for Monoclonal Antibodies Targeting Siglec-15</p>
<p><a href="http://alethiabio.com/wp-content/uploads/2013/02/Alethia-130219-EN.pdf">Alethia 130219 EN</a></p>
]]></content:encoded>
			<wfw:commentRss>http://alethiabio.com/alethia-biotherapeutics-announces-issuance-of-a-japanese-patent-for-monoclonal-antibodies-targeting-siglec-15/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Test Webmaster</title>
		<link>http://alethiabio.com/test-webmaster/</link>
		<comments>http://alethiabio.com/test-webmaster/#comments</comments>
		<pubDate>Thu, 08 Nov 2012 03:04:10 +0000</pubDate>
		<dc:creator>Mario</dc:creator>
				<category><![CDATA[Non classé]]></category>

		<guid isPermaLink="false">http://alethiabio.com/?p=869</guid>
		<description><![CDATA[Integer posuere erat a ante venenatis dapibus posuere velit aliquet.]]></description>
			<content:encoded><![CDATA[<p>Aenean eu leo quam. Pellentesque ornare sem lacinia quam venenatis vestibulum. Donec id elit non mi porta gravida at eget metus. Donec sed odio dui. Cras mattis consectetur purus sit amet fermentum. Morbi leo risus, porta ac consectetur ac, vestibulum at eros. Nullam id dolor id nibh ultricies vehicula ut id elit. Nullam quis risus eget urna mollis ornare vel eu leo.</p>
<p>Maecenas sed diam eget risus varius blandit sit amet non magna. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla vitae elit libero, a pharetra augue. Cras mattis consectetur purus sit amet fermentum. Aenean lacinia bibendum nulla sed consectetur. Maecenas faucibus mollis interdum. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus.</p>
<p>Donec ullamcorper nulla non metus auctor fringilla. Etiam porta sem malesuada magna mollis euismod. Aenean lacinia bibendum nulla sed consectetur. Donec sed odio dui. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer posuere erat a ante venenatis dapibus posuere velit aliquet. Maecenas faucibus mollis interdum.</p>
]]></content:encoded>
			<wfw:commentRss>http://alethiabio.com/test-webmaster/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>November 1, 2012</title>
		<link>http://alethiabio.com/november-1-2012/</link>
		<comments>http://alethiabio.com/november-1-2012/#comments</comments>
		<pubDate>Thu, 01 Nov 2012 16:08:03 +0000</pubDate>
		<dc:creator>Mario</dc:creator>
				<category><![CDATA[2012]]></category>

		<guid isPermaLink="false">http://alethiabio.com/?p=839</guid>
		<description><![CDATA[Alethia Biotherapeutics Closes a $4.7 Million Financing to Advance its Bone Antiresorptive Program Alethia 121101 EN]]></description>
			<content:encoded><![CDATA[<p>Alethia Biotherapeutics Closes a $4.7 Million Financing to Advance its Bone Antiresorptive Program</p>
<p><a href="http://alethiabio.com/wp-content/uploads/2012/11/Alethia-121101-EN.pdf">Alethia 121101 EN</a></p>
]]></content:encoded>
			<wfw:commentRss>http://alethiabio.com/november-1-2012/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>October 12-15, 2012</title>
		<link>http://alethiabio.com/october-12-15-2012/</link>
		<comments>http://alethiabio.com/october-12-15-2012/#comments</comments>
		<pubDate>Fri, 26 Oct 2012 17:02:28 +0000</pubDate>
		<dc:creator>Mario</dc:creator>
				<category><![CDATA[2012]]></category>

		<guid isPermaLink="false">http://alethiabio.com/?p=827</guid>
		<description><![CDATA[Alethia Biotherapeutics to be part of the ASBMR 2012 Annual Meeting  in Minneapolis, Minnesota, USA. Drs. Julie Laurin and Gilles Tremblay will be in attendance.]]></description>
			<content:encoded><![CDATA[<p>Alethia Biotherapeutics to be part of the ASBMR 2012 Annual Meeting  in Minneapolis, Minnesota, USA.</p>
<p>Drs. Julie Laurin and Gilles Tremblay will be in attendance.</p>
]]></content:encoded>
			<wfw:commentRss>http://alethiabio.com/october-12-15-2012/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>July 23, 2012</title>
		<link>http://alethiabio.com/july-23-2012/</link>
		<comments>http://alethiabio.com/july-23-2012/#comments</comments>
		<pubDate>Sun, 22 Jul 2012 16:41:27 +0000</pubDate>
		<dc:creator>Mario</dc:creator>
				<category><![CDATA[2012]]></category>

		<guid isPermaLink="false">http://alethiabio.com/?p=800</guid>
		<description><![CDATA[Alethia Biotherapeutics Obtains a Notice of Allowance for a Patent for the Use of Anti-Siglec-15 Antibodies Alethia Press Release 120723 EN]]></description>
			<content:encoded><![CDATA[<p>Alethia Biotherapeutics Obtains a Notice of Allowance for a Patent for the Use of Anti-Siglec-15 Antibodies</p>
<p><a href="http://alethiabio.com/wp-content/uploads/2012/07/Alethia-Press-Release-120723-EN.pdf">Alethia Press Release 120723 EN</a></p>
]]></content:encoded>
			<wfw:commentRss>http://alethiabio.com/july-23-2012/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>May 1, 2012</title>
		<link>http://alethiabio.com/may-1-2012/</link>
		<comments>http://alethiabio.com/may-1-2012/#comments</comments>
		<pubDate>Tue, 01 May 2012 12:36:35 +0000</pubDate>
		<dc:creator>Mario</dc:creator>
				<category><![CDATA[2012]]></category>
		<category><![CDATA[Press Release]]></category>

		<guid isPermaLink="false">http://alethiabio.com/?p=755</guid>
		<description><![CDATA[Alethia Biotherapeutics Announces Issuance of a Patent for the Use of Anti-Resorptive Antibodies for Treatment of Severe Bone Loss Alethia Press Release 120501 EN &#160;]]></description>
			<content:encoded><![CDATA[<p>Alethia Biotherapeutics Announces Issuance of a Patent for the Use of Anti-Resorptive Antibodies for Treatment of Severe Bone Loss</p>
<p><a href="http://alethiabio.com/wp-content/uploads/2012/05/Alethia-Press-Release-120501-EN1.pdf">Alethia Press Release 120501 EN</a></p>
<p>&nbsp;</p>
]]></content:encoded>
			<wfw:commentRss>http://alethiabio.com/may-1-2012/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
